Picture [LSUS] – The Business Web Portal 650x65px
Document › Details

Juno Therapeutics, Inc.. (9/9/15). "Press Release: Juno Therapeutics to Present at the 2015 Morgan Stanley Global Healthcare Conference". Seattle, WA.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation Juno Therapeutics Inc.
  Group Celgene (Group)
  Organisation 2 Morgan Stanley (Group)
Products Product Morgan Stanley Global Healthcare Conference 2015 New York
  Product 2 CAR-T technology (Chimeric Antigen Receptor T-Cell technology)
Index term Index term Juno Therapeutics–Morgan Stanley: investor conference, 201509 supply service Juno presents at Morgan Stanley Global Healthcare Conference NY
Persons Person Harr, Steve (Sana Biotechnology 201901– CEO before Juno Therapeutics 201509 CFO + Head Corporate Development)
  Person 2 Levitsky, Hy (Juno Therapeutics 201509 EVP Research + CSO before Roche Head Cancer Immunology Experimental Medicine)

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 2015 Morgan Stanley Global Healthcare Conference at 4:15 p.m. ET on Wednesday, September 16, 2015. The presentation will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development and Hy Levitsky, Juno’s Executive Vice President, Research and Chief Scientific Officer.

The webcast will be accessible on the Investors page of Juno's website at A replay of the presentation will be available at the same location for 30 days following the conference.

About Juno Therapeutics, Inc.

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St Jude Children’s Research Hospital.

Juno Forward Looking Statements

This press release contains forward-looking statements, including statements regarding Juno’s participation in the 2015 Morgan Stanley Global Healthcare Conference, as well as the subject matter of Juno's presentation at that conference. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno's dependence on Celgene for the development and commercialization outside of North America of product candidates for which Celgene exercises an option; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see Juno's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2015 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.

Investor Relations Contact:
Juno Therapeutics, Inc.
Nicole Keith, 206-566-5521


Media Contact:
W2O Group
Julie Normart, 415-946-1087

Record changed: 2017-10-01


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Celgene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 650x65px

» top